Director Daniel Apel to offer 100,000 ARWR common shares (NASDAQ: ARWR)
Arrowhead Pharmaceuticals (NASDAQ: ARWR) director Daniel Apel has filed an amended Form 144/A, signaling an intent to sell 100,000 common shares. These shares were originally awarded as compensation (a bonus) on April 15, 2025. The filing serves as a regulatory notice of proposed resale and does not confirm that the sale has been executed.
James Hamilton to sell 10,000 shares (ARWR) after prior 10,000-share sale
James Hamilton filed a Form 144/A indicating a proposed sale of 10,000 shares of Arrowhead Pharmaceuticals (ARWR). This follows a previous sale of 10,000 shares on March 5, 2026, for over $641,000. The filing also detailed several compensation issuances to Hamilton on January 4, 2026.
Insider Hongbo Lu notifies sale of 2,970 ARWR shares (NASDAQ: ARWR)
Hongbo Lu, an insider at Arrowhead Pharmaceuticals (NASDAQ: ARWR), has filed a Form 144/A notifying a proposed sale of 2,970 shares of common stock, valued at an aggregate amount of $228,298.95. The filing indicates that the sale is related to compensation and was filed on May 12, 2026, with the securities acquired on March 15, 2026. This regulatory notice informs the market of the intended transaction but does not confirm its completion.
Arrowhead Pharmaceuticals eyes $4B Redemplo opportunity as RNAi pipeline readouts near
Arrowhead Pharmaceuticals is preparing for significant data readouts from its RNAi pipeline, particularly focusing on its lead Duchenne muscular dystrophy program, ARO-DMD, and the $4 billion Redemplo opportunity. The company is strategically advancing its clinical programs and anticipates key milestones that could impact its valuation and future growth.
Arrowhead Licenses ARO PNPLA3 To Madrigal To Expand MASH Options
Arrowhead Pharmaceuticals has licensed its ARO-PNPLA3 RNAi therapeutic to Madrigal Pharmaceuticals for the development and commercialization of treatments for MASH. This agreement, which includes potential milestone and royalty revenues, allows Arrowhead to advance its RNAi platform in liver and metabolic diseases without bearing the full cost of late-stage development. The deal highlights Arrowhead's strategy of leveraging partnerships for non-dilutive capital and expanded market access, while also presenting both risks and rewards for investors regarding profitability and competition.
Baader Bank Aktiengesellschaft Purchases Shares of 14,194 Arrowhead Pharmaceuticals, Inc. $ARWR
Baader Bank Aktiengesellschaft recently acquired 14,194 shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the fourth quarter, valuing the new position at approximately $912,000. This investment comes as Arrowhead Pharmaceuticals reported a smaller-than-expected quarterly loss and while analyst sentiment remains positive with a "Moderate Buy" consensus rating and an average price target of $87.80. Other institutional investors have also increased their holdings in Arrowhead, though some insider selling has occurred.
Arrowhead (NASDAQ: ARWR) director sells 2,970 shares under Rule 10b5-1 plan
Arrowhead Pharmaceuticals director Hongbo Lu sold 2,970 shares of company stock at $76.88 per share through a pre-arranged Rule 10b5-1 trading plan. After this transaction, Lu directly owns 52,012 shares, which include restricted stock units subject to vesting. The sale, recorded on May 12, 2026, was detailed in an SEC Form 4 filing.
Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ: ARWR)
This article provides a compilation of recent news headlines related to Arrowhead Pharmaceuticals (NASDAQ:ARWR), highlighting its activities in the RNAi therapy space. Key news includes the company eyeing a $4 billion opportunity with REDEMPLO, strong Q2 2026 earnings, FDA approval for its first drug, and significant stock movements driven by clinical trial results, analyst upgrades, and collaborations. The collection also touches on broader biotech market trends and the performance of related companies.
Arrowhead Pharmaceuticals stock hits 52-week high at $80.5 By Investing.com
Arrowhead Pharmaceuticals (ARWR) stock reached a 52-week high of $80.5, bringing its market capitalization to $11.24 billion, reflecting a 438.3% increase over the past year. Despite trading above its Fair Value and being unprofitable, the company maintains a "GOOD" financial health score, recently reporting better-than-expected Q2 2026 earnings and revenue. This surge indicates strong investor confidence, though the stock saw an aftermarket decline after the positive financial results.
Arrowhead Pharmaceuticals stock hits 52-week high at $80.5
Arrowhead Pharmaceuticals Inc. stock has reached a new 52-week high of $80.5, bringing its market capitalization to $11.24 billion after a 438.3% increase over the past year. Despite being deemed "Most Overvalued" by InvestingPro data, with negative earnings per share, the company recently reported better-than-expected Q2 2026 results. This includes a narrower loss per share of -$0.93 and revenue of $74 million, surpassing analyst forecasts.
[144] ARROWHEAD PHARMACEUTICALS, INC. SEC Filing
This article announces an SEC Form 144 filing by Arrowhead Pharmaceuticals, Inc. (ARWR) regarding a proposed sale of securities. The filing details include the sale of 2970 shares of Common stock by Hongbo Lu, acquired through compensation, with an aggregate market value of $228,298.95. The notice also confirms that no securities of the issuer were sold by the person during the past three months.
Arrowhead Pharmaceuticals Jumps 7.9% After RBC Capital Maintains Outperform
Arrowhead Pharmaceuticals (ARWR) saw a 7.9% increase in its stock price, closing at $78.40, following RBC Capital's decision to maintain an "Outperform" rating and raise its price target from $80 to $87. This uplift reflects increased confidence in the biotechnology company's pipeline and commercial prospects. The rally was accompanied by heightened trading volume and suggests that analyst revisions can significantly influence biotech stock movement.
Arrowhead Pharmaceuticals (ARWR) Q1 Profit Supports Bullish Narrative Despite High 54x P/E
Arrowhead Pharmaceuticals (ARWR) reported Q1 2026 revenue of US$264.0 million and basic EPS of US$0.22, moving into profitable territory over the last year. Despite a high trailing P/E of 54x compared to industry averages and lumpy revenue driven by milestone payments, the company's TTM net income is US$202.3 million with a DCF fair value significantly above its current share price. The article discusses both bullish points, such as an expanding RNAi pipeline, and bearish concerns like revenue fluctuation and slower projected growth compared to the broader market.
Arrowhead Pharmaceuticals’ Earnings Call: Launch, Losses, Bets
Arrowhead Pharmaceuticals highlighted a strong start for its new drug REDEMPLO, compelling data for plozasiran, and a fortified balance sheet during its Q2 earnings call. Despite widening losses and nascent product revenue, the company has multiple clinical catalysts ahead, including late-stage readouts in 2026, and is expanding its RNAi pipeline and global regulatory footprint. The firm completed a significant capital raise, securing nearly $1.8 billion in cash to support its ambitious development plans.
ARWR Maintained by RBC Capital -- Price Target Raised to $87.00
RBC Capital has maintained an "Outperform" rating on Arrowhead Pharma (ARWR) and increased its price target from $80.00 to $87.00, reflecting confidence in the company's growth potential. While the stock is considered undervalued by about 6.9% according to GuruFocus's GF Value, insider activity shows a significant sell-off, prompting careful consideration for investors. ARWR's GF Score™ of 65/100 indicates moderate long-term return potential, with strong financial strength but challenges in profitability and growth.
RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $87 From $80, Maintains Outperform Speculative Risk Rating
RBC Capital has increased its price target for Arrowhead Pharmaceuticals to $87 from $80, while maintaining an Outperform Speculative Risk rating. The adjustment reflects RBC Capital's updated outlook for the biotechnology company. This news comes amidst other recent developments for Arrowhead, including its Q2 2026 earnings call and licensing deals.
Q2 2026 Arrowhead Pharmaceuticals Inc Earnings Call Transcript
This article provides the transcript for Arrowhead Pharmaceuticals Inc.'s Q2 2026 earnings call. It lists key participants from the company's management, including the President and CEO, Head of Global Cardio/Bolo Franchise, Chief Medical Officer, and Chief Financial Officer. The transcript outlines the agenda for the call, which includes overviews of company results, commercialization activities, development programs, and financial reviews.
Arrowhead Pharmaceuticals Swings to Fiscal Q2 Loss, Revenue Falls
Arrowhead Pharmaceuticals reported a swing to a fiscal Q2 loss and a decline in revenue. The company posted a Q2 loss of $0.93 per share, which was better than FactSet's estimated loss of $1.10 per share, with revenue falling to $73.7 million, narrowly missing the FactSet estimate of $73.8 million. This financial update follows several recent developments, including licensing agreements and analyst ratings.
ARROWHEAD PHARMACEUTICALS ($ARWR) Releases Q2 2026 Earnings
Arrowhead Pharmaceuticals (ARWR) announced its Q2 2026 earnings, reporting -$0.93 per share, which beat analyst estimates. However, the company's revenue of $73,740,000 missed expectations. The article also details significant insider selling activity, hedge fund movements, and recent analyst ratings and price targets for ARWR stock.
Arrowhead (NASDAQ: ARWR) swings to loss as REDEMPLO launch and big financings reshape outlook
Arrowhead Pharmaceuticals reported a significant swing to a net loss of $132.7 million in Q2 fiscal 2026, down from a net income of $370.4 million a year earlier, primarily due to a sharp decline in revenue. Despite the loss, the company substantially strengthened its balance sheet to $1.78 billion in cash through $930 million in concurrent offerings and is showing encouraging commercial traction for its REDEMPLO drug, alongside advancements in its RNAi pipeline and a licensing deal with Madrigal Pharmaceuticals. The strategic financial moves and pipeline progression provide a strong funding runway for both commercialization efforts and future development.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) posts Q2 2026 loss as prior milestone revenue fades
Arrowhead Pharmaceuticals reported a significant net loss of $132.7 million for Q2 2026, a sharp contrast to the previous year's net income, primarily due to a substantial drop in milestone revenue from collaborations, particularly with Sarepta. Despite this, the company maintains a strong liquidity position with $188.5 million in cash and $1.60 billion in available-for-sale securities, supporting its growing R&D investments and collaborations with Sarepta, Novartis, and Sanofi. The report highlights increased R&D expenses as Arrowhead advances its RNAi pipeline and prepares for commercialization, with several drug candidates showing promising clinical results and regulatory approvals for REDEMPLO (plozasiran).
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
Arrowhead Pharmaceuticals announced its fiscal 2026 second-quarter results, highlighting strong commercial momentum for REDEMPLO® (plozasiran) with over 400 prescriptions and positive regulatory actions in Australia, Europe, China, and Canada. The company also reported advancements in its RNAi pipeline, including promising clinical data for obesity candidates and a licensing agreement for ARO-PNPLA3, while significantly strengthening its balance sheet through public offerings totaling $930 million.
Arrowhead Pharma earnings up next: First Redemplo sales in focus
Arrowhead Pharmaceuticals Inc. is preparing to announce its fiscal third-quarter results, with investor focus primarily on the initial commercial sales of its new drug, Redemplo, for familial chylomicronemia syndrome. Analysts expect a loss of $1.04 per share, but Redemplo's performance and upcoming Phase 3 trial results for its severe hypertriglyceridemia treatment, Plozasiran, are key to justifying the company's high market capitalization. The company's stock has seen significant growth, and analysts maintain a Buy rating with a price target implying further upside.
Arrowhead Pharma earnings up next: First Redemplo sales in focus
Arrowhead Pharmaceuticals Inc. is preparing to report fiscal third-quarter results, with the market keenly focused on the initial commercial sales performance of its newly launched drug, Redemplo, for familial chylomicronemia syndrome. Analysts anticipate a loss of $1.04 per share on revenues of $71.5 million, reflecting a shift from partnership payments to commercial revenue generation. The company's stock has seen significant growth, and investors are also watching updates on its obesity pipeline and progress in expanding Redemplo's indications.
FMR LLC reports 5.2% stake in Arrowhead Pharmaceuticals (NASDAQ: ARWR)
FMR LLC has filed a Schedule 13G, disclosing a beneficial ownership of 7,349,106.75 shares of Arrowhead Pharmaceuticals common stock, which represents a 5.2% stake in the company. The filing specifies that FMR LLC holds sole voting power over 7,323,647.12 shares and sole dispositive power over 7,349,106.75 shares. This disclosure provides transparency regarding significant ownership in Arrowhead Pharmaceuticals for investment purposes.
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Arrowhead Pharmaceuticals has licensed its clinical-stage MASH program, ARO-PNPLA3, to Madrigal Pharmaceuticals in an exclusive worldwide agreement. ARO-PNPLA3 targets the PNPLA3 gene mutation, prevalent in Hispanic MASH patients, showing significant liver fat reduction in Phase 1 trials. Madrigal will make an upfront payment of $25 million, with Arrowhead eligible for up to $975 million in milestones and tiered royalties.
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Arrowhead Pharmaceuticals has announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, its clinical-stage RNA interference therapeutic targeting MASH. Madrigal will make an upfront payment of $25 million, with Arrowhead eligible for up to $975 million in development, regulatory, and sales milestones, plus tiered royalties. This collaboration leverages ARO-PNPLA3's compelling Phase 1 data, which showed significant liver fat reduction in patients with the PNPLA3 I148M mutation, positioning Madrigal to advance the program given their leadership in the MASH space.
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset
Madrigal Pharmaceuticals has acquired the global rights to Arrowhead Pharmaceuticals’ siRNA asset, ARO-PNPLA3, for the treatment of MASH in a deal potentially worth $1 billion. This marks Madrigal's second major siRNA investment in 2026, aiming to explore combination therapies with its FDA-approved lead drug Rezdiffra, especially for genetically predisposed patient populations. ARO-PNPLA3 has shown promising Phase I results by significantly reducing liver fat.
Arrowhead Pharmaceuticals stock hits 52-week high at 77.23 USD
Arrowhead Pharmaceuticals Inc. (ARWR) stock has reached a new 52-week high of $77.23, marking a 446% appreciation over the past year. Despite its current valuation being considered overvalued by InvestingPro analysis, the company's strategic developments and advancements in its RNAi portfolio, including a recent licensing agreement with Madrigal Pharmaceuticals and positive analyst ratings, have fueled investor confidence and market growth.
JPMorgan Expects Arrowhead Pharma Stock to Rally on RNAi Portfolio Growth
JPMorgan initiated coverage on Arrowhead Pharmaceuticals (ARWR) with an Overweight rating and an $88 price target, citing the company's diversified RNAi pipeline. The firm is particularly interested in the upcoming Phase III results for plozasiran, which targets a large market for severe hypertriglyceridemia, and its early-stage obesity programs. With a strong balance sheet and multiple catalysts ahead, JPMorgan sees Arrowhead Pharma as an attractive biotech opportunity.
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced its participation in multiple events throughout May 2026, including investor conferences and scientific congresses. These events will feature presentations on their RNAi therapeutics across various disease areas, including a fireside chat at the BofA Securities 2026 Healthcare Conference and presentations on their TRiM™ SC platform and drug candidates like Plozasiran. The company also highlights its commercial-stage status and broad portfolio of RNAi treatments.
Is Arrowhead Pharmaceuticals (ARWR) Stock Price Out Of Line With Recent 1-Year Surge?
This article analyzes Arrowhead Pharmaceuticals' (ARWR) stock valuation using Discounted Cash Flow (DCF) and Price/Earnings (P/E) ratios. The DCF analysis suggests the stock is undervalued by 48.5%, while the P/E ratio indicates it is overvalued compared to industry averages and its "Fair Ratio." The article also presents "Narratives" that offer both bullish and bearish perspectives on ARWR's future fair value based on different growth assumptions.
Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential
TD Cowen reiterated its Buy rating on Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) on March 26, citing its obesity and metabolic illness initiatives. While initial data from a related program showed mixed results, Arrowhead is expanding studies for its INHBE program due to promising signals in Type 2 diabetes. The firm anticipates further data later in the year, particularly sHTG data in the third quarter, for Arrowhead's pipeline which includes Plozasiran, Zodasiran, ARO-DIMER-PA, and ARO-PNPLA3.
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Vanguard Group Inc.
Vanguard Group Inc. reduced its stake in Arrowhead Pharmaceuticals (ARWR) by 4.6% in the fourth quarter, selling 742,749 shares but still retaining 11.25% of the company. Despite an EPS miss, Arrowhead reported strong revenue growth of over 10,461% year-over-year. Analysts generally hold a positive outlook on the stock, with a consensus "Moderate Buy" rating.
ARWR Initiates Coverage By JP Morgan -- Rating Set to Overweight
JP Morgan has initiated coverage on Arrowhead Pharmaceuticals (ARWR) with an "Overweight" rating and a price target of $88.00, suggesting potential outperformance in the biotechnology sector. GuruFocus rates ARWR as 5.9% undervalued with a moderate GF Score™ of 68/100, though insider selling worth $2.3 million has occurred in the past three months, and the company faces profitability challenges. Investors are advised to consider both the positive analyst outlook and the insider activity before making investment decisions.
ARWR SEC Filings - Arrowhead Pharma 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Arrowhead Pharma (ARWR) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. These documents offer detailed insights into the company's RNA interference pipeline, capital structure, collaborations, and key developments like drug approvals and clinical data. The platform features AI-powered summaries and real-time updates from EDGAR to assist investors in tracking regulatory disclosures.
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran) for familial chylomicronemia syndrome (FCS), making it the first and only approved treatment for FCS in Australia. This approval, based on positive Phase 3 PALISADE study results showing significant triglyceride reduction and decreased acute pancreatitis incidence, expands global access to the medicine for adult patients with genetically confirmed or clinically diagnosed FCS. REDEMPLO, already approved in the U.S., Canada, and China, is designed to silence apoC-III, a key regulator of triglyceride metabolism.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Eleven research firms have issued a "Moderate Buy" consensus rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR), with an average 12-month price target of $83.78. This comes despite recent insider stock sales totaling over $2.3 million and a Q1 earnings per share miss, though revenue exceeded estimates. Institutional investors have increased their positions in the company, which is a clinical-stage biopharmaceutical firm focused on RNA interference therapeutics.
JPMorgan initiates Arrowhead Pharma stock coverage with overweight rating
JPMorgan has initiated coverage on Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) with an overweight rating and a price target of $88.00, citing the company's diversified RNAi portfolio and strong commercial launch momentum for its first product, Redemplo. The stock has seen a significant 423% surge over the past year, trading near its 52-week high. Analysts do not anticipate profitability this year despite the strong launch and upcoming data readouts from various programs.
Arrowhead Pharmaceuticals | SCHEDULE 13G: Others
This article provides a document related to a SCHEDULE 13G filing for Arrowhead Pharmaceuticals, indicating actions taken by "Others" in connection with the company. The specific details of the filing are contained within the document itself.
5 Most Profitable Biotech Stocks to Buy Now
This article lists the 5 most profitable biotech stocks to buy now, presenting the first entry, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR). It discusses Arrowhead's drug pipeline and recent analyst comments regarding its obesity and metabolic illness initiatives. The article also includes a promotional section for an AI-related investment opportunity.
Vanguard reports 5.05% stake in Arrowhead Pharmaceuticals (ARWR)
Vanguard Capital Management has reported a 5.05% stake in Arrowhead Pharmaceuticals (ARWR) through a Schedule 13G SEC filing. This disclosure indicates beneficial ownership of 7,081,293 shares, with sole voting power over 1,048,877 shares and sole dispositive power over all 7,081,293 shares. The filing, signed on April 29, 2026, signifies a passive investment intended for informational transparency rather than active influence over the company.
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Acquired by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA significantly increased its stake in Arrowhead Pharmaceuticals (ARWR) by 253.5% in the fourth quarter, now owning 1,028,736 shares valued at approximately $68.64 million. This comes as Arrowhead reported strong revenue growth, up 10,461% year-over-year to $264.03 million, despite an EPS miss. Analyst sentiment remains largely positive, with an average target price of $83.78, while institutional ownership stands at 62.61%.
Vanguard Portfolio Management (NASDAQ: ARWR) reports 5.19% stake in Arrowhead
Vanguard Portfolio Management has disclosed a 5.19% beneficial ownership stake in Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), totaling 7,269,957 shares. This passive investment, reported via a Schedule 13G filing, indicates Vanguard has sole dispositive power over all these shares but sole voting power over only 123,821 shares. The holdings are distributed across various Vanguard funds and managed accounts.
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome in Europe
Arrowhead Pharmaceuticals has received a positive opinion from the European Medicines Agency's CHMP, recommending the approval of REDEMPLO (plozasiran) for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) in Europe. If approved by the European Commission, REDEMPLO will be the first and only siRNA medicine authorized in the EU for both genetically and clinically diagnosed adult FCS patients. This recommendation is supported by strong clinical data from the Phase 3 PALISADE study, which showed significant reductions in triglycerides and acute pancreatitis incidence.
BlackRock holds 12.2% of Arrowhead Pharmaceuticals (NASDAQ: ARWR) in 13G/A
BlackRock, Inc. has reported a beneficial ownership of 17,104,084 shares, or 12.2%, of Arrowhead Pharmaceuticals' Common Stock as of March 31, 2026. This information was disclosed in an amended Schedule 13G/A filing, indicating a passive investment intent. BlackRock maintains sole voting power for 16,769,679 shares and sole dispositive power for all 17,104,084 shares.
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
Arrowhead Pharmaceuticals announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (EMA CHMP) has adopted a positive opinion recommending the approval of REDEMPLO® (plozasiran) for familial chylomicronemia syndrome (FCS) in adults. This siRNA medicine aims to reduce triglyceride levels, which are extremely high in FCS patients and lead to a substantially higher risk of acute pancreatitis. The recommendation is based on positive results from the Phase 3 PALISADE study, showing a median 80% reduction in triglycerides and significantly fewer cases of acute pancreatitis with REDEMPLO.
M&T Bank Corp Purchases 231,620 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
M&T Bank Corp significantly increased its stake in Arrowhead Pharmaceuticals, purchasing an additional 231,620 shares in the fourth quarter to own a total of 240,634 shares valued at $15.98 million. This comes as insider James C. Hamilton sold 10,000 shares, reducing his position. Despite missing quarterly EPS estimates, Arrowhead Pharmaceuticals reported a substantial year-over-year revenue increase and holds a "Moderate Buy" consensus rating from analysts with an average target price of $83.78.
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) CFO Sells 13,095 Shares of Stock
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) CFO Daniel Apel sold 13,095 shares of the company's stock on April 22nd for a total of $934,328.25. The sale was executed under a pre-arranged Rule 10b5-1 trading plan to cover tax withholding obligations from vested equity awards, reducing his ownership by 7.44%. The stock currently trades around $73.91, with analysts maintaining a "Moderate Buy" consensus and an average price target of $83.78.
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider Sells 10,000 Shares of Stock
James Hamilton, an insider at Arrowhead Pharmaceuticals (NASDAQ:ARWR), sold 10,000 shares of the company's stock on April 23rd for $750,000, reducing his stake by 4.22%. The sale was part of a pre-arranged Rule 10b5-1 trading plan. The company is trading near its 52-week high, has a market cap of $10.35 billion, and despite missing recent EPS estimates, reported significant revenue growth and has received several analyst upgrades with a consensus target price of $83.78.
